Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation
Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.
On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.
If you are a Health Care Professional and interested in further details (including pathways being explored, mechanisms of action of investigational compounds, and an overall summary of investigational compounds organized by therapy area and disease state), please visit our in-depth Pfizer Immunology & Inflammation Research Pipeline site.
Inflammation Immunology Pipeline & Trials
Immunology Pipeline as of July 28, 2020
- Discovery Projects
- 3Phase 1
- 17Phase 2
- 3Phase 3
- 0Registration
- Total23
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
abrocitinib (PF-04965842) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK1 Inhibitor | Atopic Dermatitis (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
ritlecitinib (PF-06651600) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC | Alopecia Areata (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor | Ankylosing Spondylitis | Phase 3 | Product Enhancement | Small Molecule |
Eucrisa (crisaborole) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PDE4 Inhibitor | Stasis Dermatitis
Project advanced | Phase 2 | Product Enhancement | Small Molecule |
Dekavil Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: IL-10 | Ulcerative Colitis (Biologic) | Phase 2 | Product Enhancement | Biologic |
Dekavil Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: IL-10 | Rheumatoid Arthritis (Biologic) | Phase 2 | New Molecular Entity | Biologic |
PF-06480605 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: TNFSF15 Blocker | Ulcerative Colitis (Biologic) | Phase 2 | New Molecular Entity | Biologic |
PF-06650833 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: IRAK4 | Rheumatoid Arthritis | Phase 2 | New Molecular Entity | Small Molecule |
PF-06650833 / brepocitinib (PF-06700841) / PF-06826647 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: IRAK4; TYK2/JAK1; TYK2 Inhibitor | Hidradenitis Suppurativa | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TEC; TYK2/JAK1 | Crohn's Disease | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TEC; TYK2/JAK1 | Vitiligo | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: JAK3/TEC; TYK2/JAK1 | Ulcerative Colitis | Phase 2 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 | Alopecia Areata | Phase 2 | Product Enhancement | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 | Psoriatic Arthritis | Phase 2 | Product Enhancement | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 | Lupus | Phase 2 | Product Enhancement | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 | Psoriasis | Phase 2 | New Molecular Entity | Small Molecule |
PF-06823859 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: interferon, beta 1, fibroblast (IFNB1) Blocker | Inflammatory Disorders (Biologic) | Phase 2 | New Molecular Entity | Biologic |
